Centralising Attention on BPH Energy’s Key Growth Drivers

Diversified player, BPH Energy Limited (ASX: BPH) holds a significant stake in oil and gas exploration company, Advent Energy Ltd that has an attractive portfolio of exploration and near-term development assets in both onshore and offshore Australia. BPH is Advent’s second largest shareholder with a direct share of 22.6 per cent.

Advent’s portfolio comprises 85% interest in the Petroleum Exploration Permit 11 (PEP 11) in the offshore Sydney Basin; and 100% interest in the Exploration Permit 386 (EP 386) and Retention Licence 1 (RL 1) in the onshore Bonaparte Basin.

Advent Aiming to Drill a Well at the Baleen target

The key objective of Advent is to drill a well at the key drilling prospect, the Baleen target, within the PEP 11 permit in 2020.

PEP 11 is an important exploration area with large scale structuring that has been evaluated to contain multi-Trillion cubic feet (Tcf) gas charged Permo-Triassic reservoirs adjacent to the greater metropolitan region of Sydney-Wollongong-Newcastle and gas pipeline network. Advent holds 85 per cent JV interest in PEP 11 through its 100 per cent owned subsidiary, Asset Energy Pty Ltd.

The company has recently terminated the RL Energy JV Agreement for PEP 11, and the JV is now focusing on the drilling of a well at the Baleen prospect subject to approvals of regulatory authorities, including NOPTA.

Undertook a Review in 2004

Advent has previously undertaken a focused seismic campaign around Baleen target in PEP 11 as a preliminary step to drilling. A review conducted in 2004 interpreted major seismically indicated gas features including Amplitude Versus Offset (AVO) anomalies, apparent Hydrocarbon Related Diagenetic Zones (HRDZ) and potential fat spots within PEP 11.

Conducted Geochemical Investigation in 2010

The 2004 seismic data was reprocessed in 2010 via a geochemical investigation that endorsed drilling of a potential exploration well in PEP11. The geochemical report supported that in comparison to the background samples, the area around the potential drilling site on the Baleen target seems best for hydrocarbon impact.

Moreover, the report discovered that the Baleen looks best to carry a higher prospect of success than other targets within the permit.

A review of 850 wildcat wells was performed subsequent to geochemical surveys that indicated that 79 per cent of the wells drilled in positive anomalies ended up in commercial oil and gas discoveries.

Advent has shown substantial gas generation and gas migration within the highly prospective PEP11 permit.

Performed High Resolution 2D Seismic Survey in April 2018

Advent conducted a high resolution 2D seismic survey in April 2018, covering about 200-line km to support the drilling of the Baleen target, about 30km to the southeast of Newcastle. In a review of previous seismic data, a drilling target at a depth of 2150 metres subsea on the Baleen prospect was identified.

Moreover, intersecting 2D lines indicated an inferred seismic amplitude anomaly area of 6000 acre (24.3 km2) at that drilling target.

The report on this drilling target demonstrated that the Bowen Basin’s Permian aged section has producing conventional gas fields at a parallel time and depth to PEP 11 permit at the Permian – Triassic age boundary.

On 31st December 2018, MEC Resources Limited (BPH 0.9 per cent interest) declared that the seismically defined shallow gas hazards were not present on the Baleen target’s proposed well location.

Advent Advancing well on EP 386 and RL 1 Permits

In addition to PEP 11 permit, the company holds 100 per cent of each of EP 386 and RL 1 (through its subsidiary Onshore Energy Pty Ltd) in the onshore northern Australia’s Bonaparte Basin, which is a highly prospective petroliferous basin, with significant oil and gas reserves.

Most of the Bonaparte basin is located offshore, encompassing 250,000 sq. km, relative just over 20,000 sq. km onshore. The potential of the Bonaparte Basin is apparent from the established oil and gas fields in both the offshore and onshore portions of the basin.

An independent audit by RISC has assessed 2C Contingent Resources of 11.5 Bcf at Weaber Gas Field covered by Advent’s RL 1 permit in Northern Territory. RISC has also evaluated considerable upside 3C Contingent Resources of 45.8 Bcf.

Advent has been granted a renewal of RL 1 in the Northern Territory by the NT Department of Primary Industry and Resources for a five-year term concluding in July 2024. The company will apply further to extend the EP 386 permit to Western Australia’s government.

BPH Scores Big with Investment in Cortical Dynamics

In addition to Advent, BPH holds a considerable stake of 4.56 per cent in the medical device technology companyCortical Dynamics Ltd, that has developed a breakthrough system for monitoring brain response towards anaesthetic agents reliably.

Cortical’s core product is BARM or Brain Anaesthesia Response Monitor, a paradigm busting technology, whose competitive advantage has been recognized by prominent anaesthesia experts across the world.

Cortical’s technology holds the potential to be applied to other EEG based markets, including drug discovery, neuro-diagnostic, developing Brain computer Interface market and drug evaluation. It can also be used for tranquiliser and pain response monitoring for trauma patients in ICUs (intensive care units). It is protected by five patent families in numerous jurisdictions across the world, comprising 22 granted patents.

Cortical has received both the CE mark and TGA approval and has now initiated its sales campaign. Moreover, its Korean distributor, Globaluck has obtained the KGMP certificate of approval for BARM (Class II Medical Device) in September.

There is significant market opportunity for Cortical’s BARM in Europe’s Total Intravenous Anaesthesia (TIVA) market, wherein a large number of major surgery cases with anaesthesia are reported every year.

It is worth noting that BPH is well-positioned to make great strides by capitalising on its high-profile investments in different sectors.

BPH settled the day’s trade at $0.001 on 27th November 2019.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above article is sponsored but NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) under discussion. We are neither licensed nor qualified to provide investment advice through this platform.

Checkout our Free Dividend Stocks Report

Specially made for income-hungry investors, Invest in growing Franked Dividends an opportunity that should not be missed.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report